This week's research shows scientists are getting closer to fighting IPF from multiple angles at once — tackling aging cells, scarring signals, and lung repair all at the same time.
FVC = how much air your lungs can push out. Higher % = healthier lungs. A typical IPF patient starts around 50–60%.
This is a computer model result — not a prescription. Always talk to your doctor before changing anything.
Researchers published a new way of thinking about IPF as part of a broader pattern of lung diseases, which could help doctors catch and treat it earlier. Another exciting study showed that blocking a protein called p16 — which causes cells to age badly and stop working — can actually reduce scarring in the lungs. Think of it like removing broken-down cars that are blocking traffic so healthy cells can move freely again.
The AI tested hundreds of drug combinations and found the best mix — including pirfenidone (an approved IPF drug), a senolytic (a medicine that clears out those damaged aging cells), and several other targeted drugs — could keep lung capacity at 69.5%. For context, healthy lungs are around 80% or above, so holding at 69.5% means slowing the disease meaningfully.
One question to ask your lung doctor at your next visit: 'Are there any clinical trials near me testing drugs that clear out aging cells in the lungs?'